Astrazeneca reported on risk of thrombosis after first dose of vaccine

In the pharmaceutical company-producer of the drug from Coronavirus Astrazeneca reported on the increased risk of thrombosis after the primary vaccination. The company has placed this company on its website.

It comes from the preparation of VAXZEVRIA. According to the study published in the British Medical Journal The Lancet, eight out of a million vaccinated person face the problem of thrombosis. Among those who received the second dose of vaccine, the share of susceptible thrombocytopenia decreases to 2.3 people, which does not differ from the indicators of non-vaccinated people.

The company has information about the effect of vaccine based on materials collected throughout the world. The study took into account the data obtained until April 30 within 14 days after the injection of the first or second dose.

Earlier in Russia approved joint tests of Vaccine Satellite Light and Astrazeneca. The goal of a joint clinical study is to study the safety and immunogenicity of the combination of drugs for the prevention of a new coronavirus infection in adults.

July 19 in Spain refused to purchase the drug Astrazeneca. The cause of the side effects of the vaccine. Thrombus appear in the patients, which is a serious threat to life and health. Prior to this, Germany, Italy, France and Denmark for the same reason abandoned the drug.

/Media reports.